“…These reports drew our attention to review. As we reviewed these reports, we came to certain observations that might be of significance to both patients and treating physicians (Heppt & Sticherling, ; Oliveira et al, ; Wang & Liu, ). We observed the following: (a) total number of the reported cases in the three published reports were only six patients; (b) male: female ratio was 2:1; (c) all of the patients were above 40 years; (d) all had history of chronic plaque psoriasis, except one; (e) initial anti‐psoriatic therapies before DAAs were: (i) traditional Chinese medicine, and ultraviolet irradiation, (ii) pegylated interferon (IFN)‐α and ribavirin, (iii) topical remedies/narrowband‐ultraviolet B (NB‐UVB); (f) the reactions developed within 23–90 days post‐initiation of DAAs; (g) all showed exacerbation of chronic plaque psoriasis, except one who developed erythrodermic psoriasis and erythema multiforme; (h) treat through, maintaining the treatment with DAAs (with greater improvement on discontinuation) in three cases and improvement in one patient within 7 weeks without withdrawal of the DAAs; (i) topical therapy and/or NB‐UVB were the main treatment options; (j) only one case required cyclosporine (erythrodermic psoriasis); (k) three patients had history of hepatic cirrhosis, a known risk factor for hepatocellular carcinoma.…”